cz
en
Country
cz
Language
en
Janssen.tv Janssen.tv MENU

The role of ARTA medicaments in mCRPC therapy

Speciality: Oncology, Urology
Language: Čeština
Broadcast type: Live conference
Duration : 00:34:45
Date: February 7, 2017

Discussion panel brings an actual view on the treatment of Metastatic Castration-Resistant Prostate Cancer, especially on the role of ARTAs and the experience from the clinical practice.

Lecturers

Dr Miloš Broďák
Urology Dr Miloš Broďák Czechia Head of the Urology Clinic, University Hospital and Faculty of Medicine, Charles University in Hradec Kralove
Jana Katolická, MD, PhD
Oncology Jana Katolická, MD, PhD Czechia Head of Department of Surgical Oncology, St. Anne´s University Hospital in Brno
Jana Obertová, MD, Ph.D
Oncology Jana Obertová, MD, PhD Slovakia National Cancer Institute, Bratislava

Other in: Oncology

PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT?
Oncology, Urology Live conference PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT? Several lecturers
EN
Metastatic Prostate Cancer
Oncology Live conference Metastatic Prostate Cancer Prof. Piotr Wysocki
Prof Heather Payne
Dr Stefan Hinz
EN
1
PL
Managament of metastatic prostate cancer: new standard of care in hormone-sensitive disease
Oncology, Urology Live conference Managament of metastatic prostate cancer: new standard of care in hormone-sensitive disease Jana Katolická, MD, PhD
Martin Romančík, MD, PhD
Otakar Čapoun, MD
CZ
1
SK
Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing
Oncology, Urology Live conference Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing Several lecturers
EN
Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Recommended
Oncology Live conference Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Iwona Skoneczna, MD, Ph.D
Prof Robert Jones
Laurenţia Nicoleta Galeş, MD, Ph.D
EN
mCPRC – assets and drawbacks of hormonal treatment in an asymptomatic or slightly symptomatic patient in pre-chemo indication
Oncology, Urology mCPRC – assets and drawbacks of hormonal treatment in an asymptomatic or slightly symptomatic patient in pre-chemo indication Prof. Milan Hora, MD, Ph.D, MBA
Jana Katolická, MD, PhD
CZ
1
SK

Other in: Urology

PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT?
Oncology, Urology PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT? Several lecturers
EN
Managament of metastatic prostate cancer: new standard of care in hormone-sensitive disease
Oncology, Urology Managament of metastatic prostate cancer: new standard of care in hormone-sensitive disease Jana Katolická, MD, PhD
Martin Romančík, MD, PhD
Otakar Čapoun, MD
CZ
1
SK
Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing
Oncology, Urology Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing Several lecturers
EN
mCPRC – assets and drawbacks of hormonal treatment in an asymptomatic or slightly symptomatic patient in pre-chemo indication
Oncology, Urology mCPRC – assets and drawbacks of hormonal treatment in an asymptomatic or slightly symptomatic patient in pre-chemo indication Prof. Milan Hora, MD, Ph.D, MBA
Jana Katolická, MD, PhD
CZ
1
SK